Regional distribution of guanine nucleotide-sensitive and guanine nucleotide-insensitive vasoactive intestinal peptide receptors in rat brain

doi:10.1016/0306-4522(92)90280-F

Neuroscience

Volume 48, Issue 4, June 1992, Pages 925-932

https://doi.org/10.1016/0306-4522(92)90280-F Get rights and content

Abstract

Based on the ability of guanine nucleotides to inhibit the binding of vasoactive intestinal peptide to its receptors, a guanosine 5′-triphosphate analog, guanylyl-imidodiphosphate, was used to differentiate two subtypes (or different functional states of a single subtype) of vasoactive intestinal peptide receptor in brain with in vitro autoradiography. In most brain regions, guanylyl-imidodiphosphate reduced vasoactive intestinal peptide binding between 40 and 60%. However, in the supraoptic nucleus, locus coeruleus, interpeduncular nucleus, facial nucleus, olfactory tubercle and periventricular hypothalamic nucleus, 80% or more of vasoactive intestinal peptide binding was inhibited. In other brain regions, including the medial geniculate, olfactory bulbs, and ventral thalamic nuclei, guanylyl-imidodiphosphate had little effect on vasoactive intestinal peptide binding. In liver, lung and intestine it also partly inhibited vasoactive intestinal peptide binding. Electrophoretic analysis of vasoactive intestinal peptide, covalently cross-linked to its receptors in brain membranes, revealed a pair of bands between 44,000 and 52,000 mol. wt, a component at 64,000 mol. wt and another at 92,000 mol. wt. All were displaceable with vasoactive intestinal peptide but guanylyl-imidodiphosphate displaced only the 64,000 mol. wt band suggesting that the GTP-sensitive vasoactive intestinal peptide receptor seen in brain sections has a molecular weight of about 61,000.

The differential sensitivity to guanylyl-imidodiphosphate suggests the existence of at least two vasoactive intestinal peptide receptor subtypes in brain, with distinct regional distribution, and may reflect differential coupling to second messenger systems.

Reference (29)

AmiranoffB. et al.
Differential effects of guanine nuclebtides on the first step of VIP and glucagon action in membranes from liver cells
Biochem. biophys. Res. Commun.
(1980)
AudigierS. et al.
Vasoactive intestinal polypeptide increases inositol phospholipid breakdown in the rat superior cervical ganglion
Brain Res.
(1986)
DurrouxT. et al.
Vasoactive intestinal polypeptide and carbachol act synergistically to induce the hydrolysis of inositol containing phospholipids in the rat superior cervical ganglion
Neurosci. Lett.
(1987)
MullerJ.-M. et al.
Functional vasoactive intestinal polypeptide (VIP) receptors in human neuroblastoma subclones that contain VIP precursor mRNA and release VIP-like substances
J. biol. Chem.
(1989)
SaidS.I.
Vasoactive intestinal polypeptide: current status
Peptides
(1984)
ShafferM.M. et al.
Autoradiographic visualization of CNS receptors for vasoactive intestinal peptide
Peptides
(1986)
TatsunoI. et al.
Demonstration of specific binding sites for pituitary adenylate cyclase activation polypeptide (PACAP) in rat astrocytes
Biochem. biophys. Res. Commun.
(1990)
WiedermannC.J. et al.
Vasoactive intestinal peptide receptors in rat spleen and brain: a shared communication network
Peptides
(1988)
BatailleD. et al.
Interactions of glucagon, gut glucagon, vasoactive intestinal peptide and secretin with liver and fat cells plasma membranes
Endocrinology
(1974)
BessonJ.
Distribution and pharmacology of vasoactive intestinal peptide receptors in the brain and pituitary
Ann. N. Y. Acad. Sci.
(1988)

CouvineauA. et al.

Molecular characteristics and peptide specificity of vasoactive intestinal peptide receptors from rat cerebral cortex

J. Neurochem.

(1986)

CouvineauA. et al.

The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonie epithelium

J. clin. Endocr. Metab.

(1985)

CourvineauA. et al.

Functional and immunological evidence for stable association of solubilized vasoactive-intestinal-peptide receptor and stimulatory guanine-nucleotide-binding protein from rat liver

Eur. J. Biochem.

(1990)

GozesI. et al.

VIP: molecular biology and neurobiological function

Molec. Neurobiol.

(1989)

Cited by (44)

Unconventional binding sites and receptors for VIP and related peptides PACAP and PHI/PHM: An update
2007, Peptides
Citation Excerpt :
However, GppHNp displaced only the 64 kDa band, suggesting that the GTP-sensitive vasoactive intestinal peptide receptor present in brain sections corresponds to a roughly 61 kDa component after subtraction of VIP molecular weight; the other components, particularly the 44–52 kDa doublet, behaved like GTP insensitive species. Hence, based on their differential sensitivity to GppNHp, at least two VIP receptor binding components are represented in the brain, with distinct regional distribution, probably reflecting differential coupling to second messenger systems [25]. The pattern of expression of these receptor subtypes was demonstrated to evolve throughout rat CNS development from embryonic day 14 (E14) to adult.
The 28-amino-acid neuropeptide VIP and related peptides PACAP and PHI/PHM modulate virtually all of the vital functions in the body. These peptides are also commonly recognized as major regulators of cell growth and differentiation. Through their trophic and cytoprotective functions, they appear to play major roles in embryonic development, neurogenesis and the progression of a number of cancer types. These peptides bind to three well-characterized subtypes of G-protein coupled receptors: VPAC1 and VPAC2 share a common high affinity in the nanomolar range for VIP and PACAP; a third receptor type, PAC1, has been characterized for its high affinity for PACAP but its low affinity for VIP. Complex effects and pharmacological behaviors of these peptides suggest that multiple subtypes of binding sites may cooperate to mediate their function in target cells and tissues. In this complex response, some of these binding sites correspond to the definition of the conventional receptors cited above, while others display unexpected pharmacological and functional properties. Here we present potential clues that may lead investigators to further characterize the molecular nature and functions of these atypical binding species.
Vasoactive intestinal peptide in the brain of a mouse model for Down syndrome
2003, Experimental Neurology
Citation Excerpt :
Recently, a GTP-insensitive PHI-preferring receptor has been identified with which VIP binds with high affinity (Pineau et al., 2001). The anatomical localization and relative abundance of GTP-sensitive and GTP-insensitive VIP receptors can be differentiated in brain by receptor binding in the presence of GTP or a stable GTP analog (Hill et al., 1994a, 1992, 1999). Animals that have experienced a dysregulation of VIP exhibited several characteristics that are similar to those described above for DS individuals and Ts65Dn mice.
The most common genetic cause of mental retardation is Down syndrome, trisomy of chromosome 21, which is accompanied by small stature, developmental delays, and mental retardation. In the Ts65Dn segmental trisomy mouse model of Down syndrome, the section of mouse chromosome 16 most homologous to human chromosome 21 is trisomic. This model exhibits aspects of Down syndrome including growth restriction, delay in achieving developmental milestones, and cognitive dysfunction. Recent data link vasoactive intestinal peptide malfunction with developmental delays and cognitive deficits. Blockage of vasoactive intestinal peptide during rodent development results in growth and developmental delays, neuronal dystrophy, and, in adults, cognitive dysfunction. Also, vasoactive intestinal peptide is elevated in the blood of newborn children with autism and Down syndrome. In the current experiments, vasoactive intestinal peptide binding sites were significantly increased in several brain areas of the segmental trisomy mouse, including the olfactory bulb, hippocampus, cortex, caudate/putamen, and cerebellum, compared with wild-type littermates. In situ hybridization for VIP mRNA revealed significantly more dense vasoactive intestinal peptide mRNA in the hippocampus, cortex, raphe nuclei, and vestibular nuclei in the segmental trisomy mouse compared with wild-type littermates. In the segmental trisomy mouse cortex and hippocampus, over three times as many vasoactive intestinal peptide-immunopositive cells were visible than in wild-type mouse cortex. These abnormalities in vasoactive intestinal peptide parameters in the segmental trisomy model of Down syndrome suggest that vasoactive intestinal peptide may have a role in the neuropathology of Down-like cognitive dysfunction.
VIP as a trophic factor in the CNS and cancer cells
2003, Peptides
The effects of vasoactive intestinal peptide (VIP) on the proliferation of central nervous system (CNS) and cancer cells were investigated. VIP has important actions during CNS development. During neurogenesis, VIP stimulates the proliferation and differentiation of brain neurons. Addition of VIP to embryonic mouse spinal cord cultures increases neuronal survival and activity dependent neurotrophic factor (ADNF) secretion from astroglial cells. VIP is an integrative regulator of brain growth and development during neurogenesis and embryogenesis. Also, VIP causes increased proliferation of human breast and lung cancer cells in vitro. VIP binds with high affinity to cancer cells, elevates the cAMP and increases gene expression of c-fos, c-jun, c-myc and vascular endothelial cell growth factor. The effects of VIP on cancer cells are reversed by VIPhybrid, a synthetic VPAC₁ receptor antagonist. VIPhyb inhibits the basal growth of lung cancer cells in vitro and tumors in vivo and potentiates the ability of chemotherapeutic drugs to kill cancer cells. Due to the high density of VPAC₁ receptors in cancer cells, VIP has been radiolabeled with $^{123} I$ , $^{18} F$ and $^{99m} Tc$ to image tumors. It remains to be determined if radiolabeled VIP analogs will be useful agents for early detection of cancer in patients.
Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity
2002, Neuropeptides
The envelope protein (gp120) of the human immunodeficiency virus produces neuronal cell death in cultures that can be prevented by co-treatment with pituitary adenylate activating peptide-38 (PACAP-38) or chemokines. To investigate the hypothesis that a functional relationship exists between these two protectants, the release of chemokines was measured in rat astrocyte cultures after PACAP-38 treatment. Chemokine analyses were performed by immunoaffinity capillary electrophoresis. Bell-shaped dose–responses for PACAP-mediated release of chemokines into the culture medium were observed with EC₅₀'s of 3×10¹⁵ M (RANTES: regulated upon activation normal T cell expressed and secreted), 3×10⁻¹¹ M (MIP-1β) and 10⁻⁷ M (MIP-1α). In addition, PACAP-mediated depletion of chemokines from cultured astrocytes exhibited inverted bell-shaped curves, with similar EC₅₀'s to those observed for chemokine measurements of the medium. Comparative studies with structurally related peptides (vasoactive intestinal peptide [VIP] and secretin) revealed that PACAP was the most potent secretagogue for RANTES on astrocyte cultures. Gp120-mediated neuronal cell death was prevented by co-treatment with PACAP-38, although the efficacy of protection varied significantly among the gp120 isolates. A bi-model dose–response was observed with EC₅₀'s of 3×10⁻¹⁵ and 3×10⁻¹¹ M. Co-treatment with neutralizing antiserum to RANTES attenuated PACAP-mediated protection from toxicity associated with gp120. In contrast to previous studies with VIP and gp120 toxicity, co-treatment with anti-MIP-1α did not affect PACAP-induced protection. These studies support the hypothesis that PACAP produces neuroprotection from gp120 toxicity, in part, through the release of RANTES and this mechanism is distinct from that observed with VIP.
The polypeptide PHI discriminates a GTP-insensitive form of vip receptor in liver membranes
2001, Neuropeptides
In early reports on¹²⁵I-VIP binding experiments in liver membranes, it has been proposed that, the VIP binding sites were partially sensitive to GTP. Here we confirm that the VIP binding sites of chicken liver membranes consisted mainly in bivalent VIP/PACAP receptors and that about 50% of the¹²⁵I-VIP binding capacity was not affected by the GTP analogue GppNHp. Part of these bivalent receptors also appeared to represent PHI binding sites. In GppNHp-treated membranes, the GTP-insensitive VIP binding sites displayed a 17-fold higher relative affinity than in control membranes for the VIP analogue PHI. Such data suggested that GTP-insensitive VIP receptors may correspond to a subclass of high-affinity PHI receptors. Cross-linking of¹²⁵I-VIP or¹²⁵I-PHI to their receptors, revealed 2 components of 48 and 60 kDa. The radiolabelling of the 60 kDa component was strongly affected by increasing concentrations of the GTP analogue but was modestly abolished by an excess of PHI. Conversely, the radiolabelling of the 48 kDa molecular form was not affected by the GTP analogue but was efficiently abolished by increasing concentrations of PHI. Taken together, the data suggest that the 48 kDa component expressed in chicken liver membranes display the properties of a GTP-insensitive VIP/PHI receptor that can be pharmacologically discriminated from the GTP-sensitive 60 kDa form, through its much higher affinity for PHI.
Expression of vasoactive intestinal peptide (VIP) receptors in human uterus
2000, Peptides
We show the existence of functional vasoactive intestinal peptide (VIP) receptors in normal human female genital tract (endometrium, myometrium, ovary and Fallopian tube) as well as in leiomyoma (a frequent uterine pathology). The correlation between VIP binding and stimulation of adenylyl cyclase activity for all studied tissues was linear (r = 0.86) suggesting the expression of VIP receptors throughout the human female genital tract. Immunodetection of VIP receptor subtypes gave different molecular weights for VPAC₁ (47 kDa primarily) and VPAC₂ (65 kDa), which may be due to different glycosylation extents. In conclusion, this study demonstrates the expression of both subtypes of VIP receptors and their functionality in human female genital tract, suggesting that this neuropeptide could play an important physiological and pathophysiological role at this level.

View all citing articles on Scopus

View full text

Regional distribution of guanine nucleotide-sensitive and guanine nucleotide-insensitive vasoactive intestinal peptide receptors in rat brain

Abstract

Biochem. biophys. Res. Commun.

Brain Res.

Neurosci. Lett.

J. biol. Chem.

Peptides

Peptides

Biochem. biophys. Res. Commun.

Peptides

Interactions of glucagon, gut glucagon, vasoactive intestinal peptide and secretin with liver and fat cells plasma membranes

Endocrinology

Distribution and pharmacology of vasoactive intestinal peptide receptors in the brain and pituitary

Ann. N. Y. Acad. Sci.

Molecular characteristics and peptide specificity of vasoactive intestinal peptide receptors from rat cerebral cortex

J. Neurochem.

The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonie epithelium

J. clin. Endocr. Metab.

Functional and immunological evidence for stable association of solubilized vasoactive-intestinal-peptide receptor and stimulatory guanine-nucleotide-binding protein from rat liver

Eur. J. Biochem.

VIP: molecular biology and neurobiological function

Molec. Neurobiol.